Intravenous Thrombolysis in Chinese Patients with Different Subtype of Mild Stroke: Thrombolysis in Patients with Mild Stroke

Weiqi Chen1,2,3,4, Yuesong Pan5, Xingquan Zhao1,2,3,4, Liping Liu1,2,3,4, Hao Li1,2,3,4, Xiaoling Liao1,2,3,4, Chunjuan Wang1,2,3,4, Yilong Wang1,2,3,4 & Yongjun Wang1,2,3,4

Thrombolysis treatment for patients with mild stroke is controversial. The aim of our study was to investigate whether patients with mild stroke or its specific etiologic subtype might benefit from rt-PA therapy. Data were derived from two cohorts of patients with and without rt-PA treatment: (1) the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) and (2) the China National Stroke Registry (CNSR) database. Patients with mild stroke (defined as National Institutes of Health Stroke Scale $\leq 5$) receiving the rt-PA therapy and without rt-PA therapy were matched in 1:2 for age, sex, stroke severity and etiologic subtype. A total of 134 rt-PA-treated patients were matched to 249 non-rt-PA-treated patients in the study. Among them, 104 (76%) rt-PA-treated patients with mild stroke had good outcome after 3 months compared with 173 (69.5%) non-rt-PA-treated matching cases (odds ratio [OR], 1.48; 95% confidence interval [CI], 0.91–2.43; $P = 0.12$).

Compared with non-rt-PA-treated group, rt-PA-treated patients had good outcome after 3 months in those with stroke subtype of large-artery atherosclerosis (LAA) (80.5% vs 65.1%; OR, 2.19; 95%CI, 1.14–4.21; $P = 0.02$). For patients with mild stroke, intravenous rt-PA treatment may be effective. Patients with stroke subtype of LAA might benefit more from rt-PA treatment.

Approximately 3 million new strokes occur every year in China, and 30% of them are mild ischemic strokes1,2. About 10 to 20% of patients with mild stroke develop a new stroke within 3 months, and most of these recurrent strokes appear within 2 days after symptom onset3,4. The intravenous rt-PA treatment was considered as one of the most effective treatments for patients with acute ischemic stroke5. However, few patients with mild stroke receive intravenous rt-PA therapy5 because that thrombolysis treatment in acute phase to those patients is controversial6. Some physicians considered that the application of rt-PA in patients with mild symptoms could increase the risk of cerebral hemorrhage7. However, previous studies showed that 29% of patients with mild or rapidly improving symptoms not receiving thrombolysis led to poor outcome8–10. Up to now, only very few patients with mild stroke were included in randomized trials of rt-PA11,12. Therefore, recurrence of stroke and other vascular events in patients with an initial mild stroke or TIA have become a frustrating medical situation5,16. Furthermore, previous study reported that different stroke etiology subtypes appeared as independent risk predictors for early worsening in patients with mild ischemic stroke17. Little is known about the influence of stroke etiology on the effect of rt-PA treatment for patients with mild stroke18.

1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 2China National Clinical Research Center for Neurological Diseases (NCRC-ND), Beijing, China. 3Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China. 4Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China. 5Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China. Weiqi Chen and Yuesong Pan contributed equally to this work. Correspondence and requests for materials should be addressed to Y.W. (email: yilong528@gmail.com) or Y.W. (email: yongjunwang1962@gmail.com)
We investigated whether patients with mild ischemic stroke could benefit from intravenous rt-PA therapy by comparing matched pairs of patients with and without receiving rt-PA. We also hypothesized that the intravenous thrombolysis may have differential contribution to prognosis of the different subtypes of mild stroke.

Results

Patient Characteristics. A total of 174 rt-PA treated patients with mild stroke and with complete baseline variables were identified in the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) registry, while 1225 non-rt-PA treated patients with mild stroke in the China National Stroke Registry (CNSR) registry. According to the predefined matching method, we matched 134 rt-PA treated patients to 249 non-rt-PA treated patients in our study (Fig. 1).

The mean age of rt-PA treated patients was 62.3 ± 10.5, and was 63.2 ± 10.6 in rt-PA untreated patients (Table 1). There were 48 patients (35.8%) in rt-PA treated group and 90 patients (36.1%) in rt-PA untreated group were female. A total of 68.7% of the patients had a history of hypertension, 17.9% had diabetes mellitus, and 7.5% had atrial fibrillation in rt-PA treated group, and the proportions were 62.7%, 23.7% and 8.4% in untreated group respectively. However, patients in untreated group had a higher proportion of history of stroke (P < 0.001).

Outcome. We compared the outcomes at 3 months after mild stroke onset in rt-PA treated patients with matched rt-PA untreated patients.

Figure 2 showed the distribution of mRS score at 3 months in matched patients with mild stroke. We found a shift toward upgraded outcome in rt-PA treated patients with mild stroke compared with rt-PA untreated patients. There were 77.6% of the patients in rt-PA treated group having good functional outcome (mRS 0–1) at 3 months, while the proportion in the untreated group was 69.5%. We found a favorable trend of better outcome in rt-PA treated patients, although the overall difference was not statistically significant (OR, 1.48; 95% CI, 0.91–2.43; P = 0.12).

In the subgroup analysis according to stroke subtype (Fig. 3), 80.5% (62/77) rt-PA treated patients with LAA had good outcome (mRS 0–1) at 3 months, compared with 65.1% (99/152) rt-PA untreated patients with LAA had good outcome at 3 months after stroke onset (OR, 2.19; 95% CI, 1.14–4.21; p = 0.02). This benefit effect was not observed in the SVO, CE and "other" determined etiology and UD subtype groups (p = 0.42, p = 0.60 and p = 0.48, respectively). The ORs with 95% CIs of rt-PA treated and untreated groups are shown in Fig. 3.

The mortality rate was 1.5% (2 of 134) in rt-PA treated patients, while 1.2% (3 of 249) in patients without rt-PA treatment (OR, 1.00; 95% CI, 0.16–6.14; p = 1.00). Only one (0.7%) patient in rt-PA treatment group had symptomatic intracranial hemorrhage (sICH) defined by ECASS II (second European-Australasian acute stroke study) criteria during three months.

Discussion

This observational study showed that mild stroke patients who received intravenous rt-PA treatment obtained a high rate (77.6%) of good outcome (mRS 0–1 at 3 months), which was similar with previous study reported. We also found that patients with mild stroke whose etiological type was LAA might benefit more from the intravenous rt-PA than other types of etiology.
The sICH incidence in mild stroke patients receiving rt-PA treatment in other studies have been reported in a range of 0% to 3.7%. Considering the baseline NIHSS was closely associated with the incidence of sICH in patients treating with rt-PA, the sICH rate was considered to be low in mild stroke patients. In the present study, the incidence of sICH was 0.78% (2/263) in the rt-PA group and 0.4% (1/250) in the non-rt-PA group. The difference was not statistically significant (p = 0.82).

Table 1. Baseline Characteristics of Matched Patients with Mild Stroke. IQR: interquartile range; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; rt-PA: recombinant tissue plasminogen activator; SD: Standard Deviation.

| Characteristics                        | rt-PA (n = 134) | Non-rt-PA (n = 249) | p     |
|----------------------------------------|----------------|---------------------|-------|
| Female, n (%)                          | 48 (35.8)      | 90 (36.1)           | 1.00  |
| Age, y (mean ± SD)                     | 62.3 ± 10.5    | 63.2 ± 10.6         | 0.06  |
| Hypertension, n (%)                    | 92 (68.7)      | 156 (62.7)          | 0.23  |
| Diabetes Mellitus, n (%)               | 24 (17.9)      | 59 (23.7)           | 0.20  |
| Atrial Fibrillation, n (%)             | 10 (7.5)       | 21 (8.4)            | 0.25  |
| History of stroke, n (%)               | 23 (17.2)      | 89 (35.7)           | <0.001|
| Smoking, n (%)                         | 63 (47.0)      | 71 (28.5)           | <0.001|
| Pre-stroke mRS 0–1                     | 129 (96.3)     | 234 (94.7)          | 0.51  |
| NIHSS, median (IQR)                    | 4 (4–5)        | 4 (4–5)             | 1.00  |
| Stroke subtype, n (%)                  |                |                     | 0.82  |
| Large artery atherosclerosis           | 77 (57.5)      | 152 (61.0)          |       |
| Small vessel occlusion                 | 30 (22.4)      | 56 (22.5)           |       |
| Cardioembolism                         | 11 (8.2)       | 18 (7.2)            |       |
| Other/Undetermined                     | 16 (11.9)      | 23 (9.2)            |       |
| Treatment during hospitalization, n (%)|                |                     |       |
| Anti-platelet                          | 121 (90.3)     | 229 (92.0)          | 0.86  |
| Anticoagulants                         | 29 (21.6)      | 77 (30.9)           | 0.01  |
| Antihypertensive                       | 57 (42.5)      | 129 (51.8)          | 0.06  |

Figure 2. Distribution of mRS scores at 3 months in matched patients with mild stroke with and without rt-PA treatment. mRS: modified Rankin Scale; rt-PA: recombinant tissue plasminogen activator.

Figure 3. Odds ratio of rt-PA treatment for patients with mild stroke. CE: cardioembolism; CI: confidence interval; LAA: large artery atherosclerosis; mRS: modified Rankin Scale; rt-PA: recombinant tissue plasminogen activator; SVO: small vessel occlusion; UD: undetermined.

The sICH incidence in mild stroke patients receiving rt-PA treatment in other studies have been reported in a range of 0% to 3.7%. Considering the baseline NIHSS was closely associated with the incidence of sICH in patients treating with rt-PA, the sICH rate was considered to be low in mild stroke patients. In the present study,
only one patient had sICH (0.7%) in rt-PA treatment group. Meanwhile, the sICH rate of patients despite of the baseline NIHSS in the overall TIMS-China study was 3.1%25. Compared with the study conducted in Korea24 with 4.1% of sICH incidence in rt-PA group, the SICH rate in our study was very low. The reason might be related to the small sample size of our study.

This analysis allowed us to estimate the effect of rt-PA in the mild stroke patients who were excluded from most randomized trials. Previous results from randomized studies14, 15 and observational cohorts27–29 demonstrated controversial results about the effectiveness of intravenous rt-PA treatment in patients with mild stroke. Our study provided data that patients with mild stroke might potentially benefit from intravenous thrombolysis, especially in those with LAA etiology subtype. It is still unknown which criteria should be used for choosing the appropriate candidates for intravenous rt-PA treatment among patients with mild stroke26. We knew that patients with LAA were more likely to experience symptom worsening than other types of etiology30. Although, in clinical practice, the etiology of the stroke usually could not be accurately determined within the short “time-window” of rt-PA treatment, we found that mild stroke patients with LAA might benefit more from rt-PA treatment than standard care.

Also, well design randomized clinical trials or larger observational studies are needed to confirm the effectiveness of intravenous thrombolytic therapy in mild ischemic stroke patients. However, given the large sample sizes required, this will create a major challenge for the design and recruitment of future randomized controlled trials. The Potential for rt-PA to Improve Strokes with Mild Symptoms (PRISMS, NCT02072226) trial31 which has closed, was designed as a double-blinded, randomized trial evaluating the efficacy and safety of intravenous rt-PA vs. aspirin 325 mg in mild stroke patients (NIHSS ≤ 5). The results of this trial are expected in the near future.

Our study also had several limitations. First, only 14.8% of patients in the CNSR registry were included in this analysis after paired matching, which might indicate potential selection bias of our study. Second, considering the fact that we only included 300 subjects in this study, it had limited power to detect the effects of thrombolysis among patients with mild stroke. The small sample size was also the potential explanation of the statistically insignificant results of the present study. Third, our study was an observational study and post hoc analysis was performed for stroke subtype; therefore, it could not provide adequate level of evidence of the overall benefit of intravenous rt-PA in mild stroke patients. The results should be further validated in well-designed randomized clinical trial. Fourth, we only reported effectiveness of rt-PA treatment in mild stroke patients, without safety index (sICH) in the rt-PA untreated patients. Finally, the matching process did not control for the variables such as the nature of the hospital or the nature of the treating physician, and the rt-PA untreated group had a higher history of stroke. This might cause bias and undermined the conclusion.

In conclusion, administering intravenous rt-PA to patients with mild stroke (NIHSS ≤ 5) may lead to potential better clinical outcome compared to not receiving thrombolysis treatment. Patients with stroke subtype of LAA might be likely to benefit from intravenous thrombolysis therapy than other stroke subtypes but need further study to verify it.

Methods
Patients receiving rt-PA treatment were derived from the TIMS-China19. Patients not receiving rt-PA treatment were derived from the CNSR20 database which was conducted as the same period as TIMS-China. From both cohorts, we extracted the following variables: age, sex, medical history (including hypertension, diabetes mellitus, atrial fibrillation, history of stroke, smoking), stroke severity (measured by National Institutes of Health Stroke Scale, NIHSS), stroke subtype and treatment during hospitalization, et al. The detailed information of screening process was showed in Fig. 1.

The good outcome of patients with mild stroke was defined as a modified Rankin Scale (mRS) of 0 to 1 at 3 months21, 23, 32. All patients with acute mild ischemic stroke were further classified according to the TOAST (Trial of Org 10172 in Acute Stroke Treatment)34 criteria: large-artery atherosclerosis (LAA), small-vessel occlusion (SAO), cardioembolism (CE), stroke of other determined etiology (other), and stroke of undetermined etiology (UD)33. The overall inter-rater agreement for the TOAST classification was good (κ value of 0.73 [95% CI, 0.65–0.81])34.

TIMS-China Cohort. TIMS-China was a national prospective stroke registry of thrombolytic therapy with intravenous rt-PA (Actilyse, Boehringer Ingelheim, Germany) in patients with acute ischemic stroke in China19. The registry enrolled 1440 consecutive patients with rt-PA treatment from 67 centers in China since May 2007 to April 2012. Data on clinical characteristics, computer tomographic (CT) or magnetic resonance imaging (MRI) scans of brain, medical therapy and intravenous thrombolysis information were collected. The data in the TIMS-China was gathered by experienced physicians with standard case report form after obtained informed consent for participating in the registry and receiving thrombolysis therapy. The follow up duration was 3 months through face to face or telephone.

CNSR Cohort. Between September 2007 and August 2008, 22 216 adult patients from 132 participating hospitals with acute stroke were recruited into the CNSR which was the first large scale nationwide stroke registry in China30. Detailed baseline data were collected through using paper-based case report forms. Trained stroke neurologists or research personnel performed data collection at baseline, 3 months, 6 months and 12 months. The interviewers were not allowed to work until having passed examination and obtained certification for the NIHSS and modified Rankin Scale (mRS). Written informed consent was obtained from all patients or their legal representatives.

Matching. Patients with mild stroke with intravenous rt-PA and without intravenous rt-PA treatment were 1:2 matched according to age, gender, stroke severity at baseline (according to NIHSS), stroke subtype (according to the TOAST criteria). We permitted a ±5 years for age between the two groups. We enforced exact matching...
for the nominal level of measurement for gender and stroke subtype (TOAST criteria). For stroke severity, we enforced exact matching from 0 to 5 points of the NIHSS. Two patients in the control group was extracted by random sampling technique if more than 3 cases were matched.

**Statistical Analysis.** Continuous variables were compared with the Student’s t test or Mann-Whitney tests as appropriate. Categorical variables were compared with Pearson’s χ² or Fisher’s exact tests. Odds ratios (ORs) with their confidence intervals (CIs) for good outcome were estimated using conditional logistic regression models in total patients and by stroke subtype, respectively. The level of significance was established at a two-tailed value of p < 0.05. All analyses were processed with SAS software version 9.3 (SAS Institute Inc, Cary, NC).

**Ethical approval.** The study was approved by both the Ethics Committee of the Beijing Tiantan Hospital, in compliance with the Declaration of Helsinki. Written informed consent was obtained from all participants. All the experiments described were performed in accordance with the approved guidelines.

**References**

1. Zhao, D. et al. Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke 39, 1668–1674, doi:10.1161/STROKEAHA.107.502807 (2008).
2. Wang, Y. L. et al. Burden of stroke in China. Int J Stroke 2, 211–213, doi:10.1111/j.1747-4949.2007.00142.x (2007).
3. Johnston, S. C., Gress, D. R., Browner, W. S. & Sidney, S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284, 2901–2906, doi:10.1001/jama.284.22.2901 (2000).
4. Coull, A. J., Lovett, J. K., Rothwell, P. M. & Oxford Vascular, S. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328, 326–0, doi:10.1136/bmj.37991635266.44 (2004).
5. Ois, A. et al. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. Stroke 39, 1717–1721, doi:10.1161/STROKEAHA.107.505438 (2008).
6. Chandraratne, A., Geraghty, O. C. & Rothwell, P. M. Poor performance of current prognostic scores for early risk of recurrence after minor stroke. Stroke 42, 632–637, doi:10.1161/STROKEAHA.110.59393–637 (2011).
7. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333, 1581–1587 (1995).
8. Cocho, D. et al. Factors for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 64, 719–720, doi:10.1221/01.WNL.0000152041.20486.2F (2005).
9. Wang, Y. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369, 11–19, doi:10.1056/NEJMoai1213340 (2013).
10. Hassan, A. E., Hassanzadeh, B., Tohidi, V. & Kirmani, J. F. Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage. South Med J 103, 398–402, doi:10.1097/SMJ.0b013e3181d7814a (2010).
11. Smith, E. E. et al. Outcome in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 42, 3110–3115, doi:10.1161/STROKEAHA.111.613820 (2011).
12. Khatri, P., Conway, M. R., Johnston, K. C. & Acute Stroke Accurate Prediction Study, I. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild stroke. Stroke 43, 560–562 (2012).
13. Nedeltchev, K. et al. Outcome and harm of stroke with mild or rapidly improving symptoms. Stroke 38, 2531–2535, doi:10.1161/STROKEAHA.107.482554 (2007).
14. Group, I. S. T. C. et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379, 2352–2363 (2012).
15. National Institute of Neurological Disorders Stroke rt, P. A. S. G. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333, 1581–1587 (1995).
16. Cocho, D. et al. Factors for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 64, 719–720, doi:10.1221/01.WNL.0000152041.20486.2F (2005).
17. Ferrari, J. et al. Early clinical worsening in patients with TIA or minor stroke: the Austrian Stroke Unit Registry. Neurology 74, 136–141, doi:10.1212/WNL.0b013e3181c9188b (2010).
18. Zhu, W. et al. Does large vessel occlusion affect clinical outcome in stroke with mild neurologic deficits after intravenous thrombolysis? J Stroke Cerebrovasc Dis 23, 2888–2893, doi:10.1016/j.jstrokecerebrovasdis.2014.07.018 (2014).
19. Liao, X. L. et al. Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients. CNS Neurosci Ther 19, 43–47, doi:10.1111/cns.2012.19.issue-1 (2013).
20. Wang, Y. et al. The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke 6, 355–361, doi:10.1111/j.1747-4949.2011.00584.x (2011).
21. Laurencin, C. et al. Thrombolysis for Acute Minor Stroke: Outcome and Barriers to Management. Results from the RESUV AL Stroke Network. Cerebrovasc Dis 40, 3–9, doi:10.1159/000381866 (2015).
22. Baumann, C. et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 37, 1332–1333, doi:10.1161/STROKEAHA.110.217272.38455.a2 (2006).
23. Kohrmann, M. et al. Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc Dis 27, 160–166, doi:10.1159/000185607 (2009).
24. Chen, W. et al. Treated risks in vascular events score predicts clinical outcome and symptomatic intracranial hemorrhage in chinese patients after thrombolysis. Stroke 46, 864–866, doi:10.1161/STROKEAHA.114.007979 (2015).
25. Liao, X. et al. Standard-dose intravenous tissue plasminogen activator for stroke is better than low doses. Stroke 45, 2354–2358, doi:10.1161/STROKEAHA.114.005998 (2014).
26. Choe, J. C. et al. Comparative effectiveness of standard care with IV thrombolysis versus IV thrombolysis for mild ischemic stroke. J Am Heart Assoc 4, e001306, doi:10.1161/JAHA.114.001306 (2015).
27. Frank, B. et al. Thrombolysis in stroke despite contraindications or warnings? Stroke 44, 727–733, doi:10.1161/STROKEAHA.112.764622 (2013).
28. Urra, X. et al. The outcome of patients with mild stroke improves after treatment with systemic thrombolysis. PloS one 8, e59420, doi:10.1371/journal.pone.0059420 (2013).
29. Stribian, D. et al. Ultra-early thrombolysis in stroke patients: do all patients benefit similarly? Stroke 44, 2913–2916, doi:10.1161/STROKEAHA.111.000819 (2013).
30. Lovett, J. K., Coull, A. J. & Rothwell, P. M. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62, 569–573, doi:10.1212/WNL.0b013e3181109970.83 (2004).
31. A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS). In: ClinicalTrials.gov [Internet]. Bethesda, Md. N. l. o. M.
32. Logallo, N., Kvistad, C. E., Naess, H., Waje-Andreassen, U. & Thomassen, L. Mild stroke: safety and outcome in patients receiving thrombolysis. *Acta Neurol Scand Suppl.* 37–40 (2014).

33. Adams, H. P. Jr. *et al.* Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 24, 35–41, doi:10.1161/01.STR.24.1.35 (1993).

34. Wang, Y. *et al.* Association of hypertension with stroke recurrence depends on ischemic stroke subtype. *Stroke* 44, 1232–1237, doi:10.1161/STROKEAHA.111.003032 (2013).

Acknowledgements

This study was supported by grants from National Key Technology Research and Development Program of the Ministry of Science and Technology of the People's Republic of China (2013BAI09B03, 2015BAI12B04 and 2015BAI12B02), a grant from Beijing Municipal Science & Technology Commission (D151100002015001), a grant from Beijing Institute for Brain Disorders (1152130306) and a grant from the National Natural Science Foundation of China (No. 81322019).

Author Contributions

W.C. and Y.P. analyzed the data and prepared for the manuscript. X.Z., L.L., H.L. planned and designed the study. X.L. and C.W. contributed to the acquisition of data. Y.W. and Y.W. conceived, designed and supervised the study. All authors reviewed and finally approved the manuscript.

Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017